Sandoz expands partnership with World Child Cancer, to help children access treatment in four developing countries

NovartisSandoz today announces the expansion of a pilot project with leading charity World Child Cancer, aimed at improving access to treatment and optimizing survival outcomes for children suffering from cancer in four developing countries. The agreement builds on an existing partnership with World Child Cancer in the Philippines, where Sandoz is funding staff training needs and helping children to access diagnosis and subsequent treatment. It expands the partnership to cover three additional countries across three continents: Ghana, Mexico and Myanmar.

These particular projects were chosen because of the gravity of the situation in the four regions concerned: across all four, an estimated 6000 children develop cancer each year, but only approximately 20% even receive a diagnosis, let alone effective treatment.

Jon Rosser, Chief Executive of World Child Cancer, said: "It is just unacceptable that children's odds of surviving cancer depend so much on geography. In developed countries, 80% now survive, but in developing countries it's still only about 10%. World Child Cancer is changing this - in our programs we can raise that survival rate to around 60%."

He added: "We are very excited at this growing partnership with Sandoz, which will enable us to prevent so many children dying without even a diagnosis and without effective pain relief. We believe that all children, regardless of where they live, deserve better."

Peter Stenico, Sandoz Head of Oncology, said: "These projects will take simple, pragmatic measures to attack cancer where it is most vulnerable: among children suffering from forms of cancer that are often absolutely treatable. Together with World Child Cancer, we believe we can make a real difference by enhancing the standard of care for children in these countries and, ultimately, improving childhood cancer survival rates."

The expanded partnership highlights Sandoz's commitment to work together with key stakeholders worldwide to expand access to healthcare. As a targeted philanthropy project, our work with World Child Cancer complements our broader Novartis Corporate Responsibility efforts across a number of lower income countries.

About Sandoz
Sandoz is a global leader in generic pharmaceuticals and biosimilars. As a division of the Novartis Group, our purpose is to discover new ways to improve and extend people's lives. We contribute to society's ability to support growing healthcare needs by pioneering novel approaches to help people around the world access high-quality medicine. Our portfolio of approximately 1000 molecules, covering all major therapeutic areas, accounted for 2016 sales of USD 10.1 billion. In 2016, our products reached well over 500 million patients and we aspire to reach one billion. Sandoz is headquartered in Holzkirchen, in Germany's Greater Munich area.

About World Child Cancer
World Child Cancer helps children with cancer access diagnosis, treatment and support in developing countries where the chances of survival can be as low as 10% compared with 80% in the developed world.

World Child Cancer does this by building partnerships between doctors and nurses at hospitals in the developed world who provide training and mentoring for doctors in developing countries. It also helps with transport, food and accommodation costs to meet the wider needs of families who have a child with cancer.

World Child Cancer programs run in some of the poorest places in the world. Last year it helped over 5,500 children but, with an estimated 200,000 unnecessary deaths each year, there is so much more that needs to be done.

Most Popular Now

Positive Phase 1 data from mRNA-based individualiz…

BioNTech SE (Nasdaq: BNTX, "BioNTech") announced initial data from an ongoing investigator-initiated first-in-human Phase 1 study evaluating the safety and tolerability o...

FDA approves RIABNI™ (rituximab-arrx), a biosimila…

Amgen (NASDAQ:AMGN) today announced that the U.S. Food and Drug Administration (FDA) has approved RIABNI™ (rituximab-arrx), a biosimilar to Rituxan®, in combination with ...

Pfizer to invest $120 million to produce COVID-19 …

Pfizer Inc. (NYSE: PFE) announced today that it will further strengthen its commitment to United States manufacturing with a $120 million investment at its Kalamazoo, Mic...

Proteomic study of 2,002 tumors identifies 11 pan-…

A new study that analyzed protein levels in 2,002 primary tumors from 14 tissue-based cancer types identified 11 distinct molecular subtypes, providing systematic knowled...

A new technology offers treatment for HIV infectio…

A new study from Tel Aviv University offers a new and unique treatment for AIDS which may be developed into a vaccine or a one time treatment for patients with HIV. The s...

Sanoff offers perspective on a promising rectal ca…

UNC Lineberger Comprehensive Cancer Center's Hanna K. Sanoff, MD, MPH, is the author of a viewpoint in the New England Journal of Medicine that provides a perspective on ...

Boehringer Ingelheim signs option to acquire Truti…

Boehringer Ingelheim announced the signing of an option to acquire Trutino Biosciences Inc. (the "Transaction"), a San Diego-based biotech company. Trutino Biosciences...

Broadly neutralizing antibodies could provide immu…

Two broadly neutralizing antibodies show great promise to provide long-acting immunity against COVID-19 in immunocompromised populations according to a paper published Ju...

Novel drug combo activates natural killer cell imm…

Most skin cancer drugs that activate the immune system work by triggering immune cells, called T cells, to attack tumors, but when T cells are activated for too long, the...

Novartis announces Nature Medicine publication of …

Novartis announced that Nature Medicine published final results from both the two- and three-copy cohorts of the completed Phase 3 SPR1NT trial as separate companion manu...

COVID-19 rebound after taking Paxlovid likely due …

Paxlovid is the leading oral medication for preventing severe cases of COVID-19 in high-risk individuals. However, symptoms returned in some patients after treatment was ...

Biomarkers found that could be drug targets agains…

Biomarkers that could be targets for novel drugs to treat glioblastoma brain tumors have been identified by investigators at Georgetown Lombardi Comprehensive Cancer Cent...